Clostridium Difficile

Feature Article

Review of Clostridium difficile Vaccines in Development

Review of Clostridium difficile Vaccines in Development

Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

A meta-analysis study shows patients who take gastric acid suppressants have a higher risk for recurrent Clostridium difficile infection.

High Rate of Metronidazole Resistance Seen in C difficile Infection

High Rate of Metronidazole Resistance Seen in C difficile Infection

Antibiotic resistance to therapies for Clostridium difficile infection are common, and their patterns should be considered in algorithms designed to select therapies.

Lower Rates of Recurrent C difficile Infections With Bezlotoxumab

Lower Rates of Recurrent C difficile Infections With Bezlotoxumab

Bezlotoxumab was particularly effective in patients with risk factors for poor outcome, including older age, immunocompromise, and severe infection.

Restricting Fluoroquinolone Use Helped With CDI Decline in England

Restricting Fluoroquinolone Use Helped With CDI Decline in England

The outbreak of Clostridium difficile in England that began in 2006 was curbed by reducing the use of fluoroquinolones, according to a study.

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

No difference in the risk of Clostridium difficile infection (CDI) recurrence observed with vancomycin or metronidazole but 30-day mortality risk was significantly lower among patients with severe CDI treated with vancomycin.

Fecal Microbiota Transplant Effective for C difficile in Pregnancy

Fecal Microbiota Transplant Effective for C difficile in Pregnancy

A 28-year-old pregnant woman who presented with recurrent C difficile infection underwent a successful fecal microbiota transplant at 18 weeks of gestation.

Oral Antibiotics as Effective as Fecal Transplant for C difficile

Oral Antibiotics as Effective as Fecal Transplant for C difficile

Results showed no real difference in outcomes when comparing fecal transplant and antibiotic treatment.

Treating C difficile Through Fecal Microbiota Transplant Cost-Effective

Treating C difficile Through Fecal Microbiota Transplant Cost-Effective

Both fecal microbiota transplant and vancomycin resulted in improved quality of life and reduced costs in patients with Clostridium difficile.

Pharmacist Intervention Encourages Adherence to C difficile Treatment

Pharmacist Intervention Encourages Adherence to C difficile Treatment

Active pharmacist intervention was found to improve adherence to C difficile treatment.

FDA: Zinplava Approved to Reduce Recurrence of C difficile  Infection

FDA: Zinplava Approved to Reduce Recurrence of C difficile Infection

FDA has approved Zinplava™ (bezlotoxumab) injection to reduce the recurrence of C difficile infection in patients at high risk.

Sign Up for Free e-newsletters